Randomised Evaluation of COVID-19 Therapy (RECOVERY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04381936 |
Recruitment Status :
Recruiting
First Posted : May 11, 2020
Last Update Posted : January 5, 2024
|
Sponsor:
University of Oxford
Collaborators:
UK Research and Innovation
National Institute for Health Research, United Kingdom
Wellcome
Bill and Melinda Gates Foundation
Department for International Development, United Kingdom
Health Data Research UK
Medical Research Council Population Health Research Unit
NIHR Clinical Trials Unit Support Funding
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
Flu Lab
Information provided by (Responsible Party):
University of Oxford
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | June 30, 2026 |
Estimated Study Completion Date : | June 30, 2036 |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
RECOVERY Collaborative Group. Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 25 September 2022. doi.org/10.1101/2022.09.23.22280285
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):